Try a new search

Format these results:

Searched for:



Total Results:


Acceptance of routine vaccines in pregnancy during the COVID-19 pandemic

Perelman, Allison; Trostle, Megan E; Pecoriello, Jillian; Quinn, Gwendolyn P; Roman, Ashley; Penfield, Christina A
OBJECTIVE:Evaluate rates of vaccination against infectious diseases (Tdap and influenza) in pregnancy during the COVID-19 pandemic compared to contemporary historical controls. STUDY DESIGN/METHODS:This was a retrospective cohort study comparing rates of Tdap and influenza vaccination in pregnant people who received care at NYU Langone Health and delivered from 9/1/2020 to 1/1/2021 ("COVID cohort") to the same period the prior year ("2019 cohort"). Demographic information, trimester of initiation of prenatal care, insurance status, and medical comorbidities were evaluated. Outcomes were analyzed using Chi- squared, Fisher's exact test, and multivariable logistic regression, with significance of p<0.05. RESULTS:1713 pregnant people were included. Compared to historical controls, the COVID cohort differed in age, race, timing of initiation of prenatal care, insurance status, and medical comorbidities. After adjusting for these covariates, pregnant people were significantly more likely to accept influenza vaccine in the COVID cohort (aOR 1.7, 95% CI 1.27-2.29) and had similar Tdap acceptance (aOR 1.5, 95% CI 0.99 - 2.17). However, this trend was not observed for the entire obstetric population; public insurance status and medical comorbidities were associated with lower vaccine rates during the pandemic. For those who had public insurance, rates of influenza vaccination decreased from 83% in 2019 to 40% during COVID (aOR 0.16, 95% CI 0.10 - 0.24) and for Tdap rates decreased from 93% to 54% (aOR 0.13, 95% CI 0.08 - 0.21). CONCLUSION/CONCLUSIONS:During the COVID-19 pandemic era, pregnant people at large were more likely to accept the influenza vaccine. However, this trend did not apply to Tdap, and did not apply to high-risk groups with public insurance and medical comorbidities. This study highlights potential disparities in vaccination rates, which need to be accounted for when evaluating national vaccine trends. These data support increased efforts in vaccine counseling for high-risk populations.
PMID: 37816391
ISSN: 1098-8785
CID: 5571572

Association between Peripartum Mean Arterial Pressure and Postpartum Readmission for Preeclampsia with Severe Features

Lin, Bing-Xue; Smith, Maria; Sutter, Megan; Penfield, Christina A; Proudfit, Christine
OBJECTIVE: This study aimed to evaluate the relationship between peripartum mean arterial pressure (MAP) and postpartum readmission for preeclampsia with severe features. STUDY DESIGN/METHODS: This is a retrospective case-control study comparing adult parturients readmitted for preeclampsia with severe features to matched nonreadmitted controls. Our primary objective was to evaluate the association between MAP at three time points during the index hospitalization (admission, 24-hour postpartum, and discharge) and readmission risk. We also evaluated readmission risk by age, race, body mass index, and comorbidities. Our secondary aim was to establish MAP thresholds to identify the population at highest risk of readmission. Multivariate logistic regression and chi-squared tests were used to determine the adjusted odds of readmission based on MAP. Receiver operating characteristic analyses were performed to evaluate risk of readmission relative to MAP; optimal MAP thresholds were established to identify those at highest risk of readmission. Pairwise comparisons were made between subgroups after stratifying for history of hypertension, with a focus on readmitted patients with new-onset postpartum preeclampsia. RESULTS: = 0.0018) were associated with increased risk of readmission. African American race and hypertensive disorder of pregnancy were independently associated with increased risk of readmission. Subjects with MAP > 99.5 mm Hg at admission or >91.5 mm Hg at 24-hour postpartum had a risk of at least 46% of requiring postpartum readmission for preeclampsia with severe features. CONCLUSION/CONCLUSIONS: Admission and 24-hour postpartum MAP correlate with risk of postpartum readmission for preeclampsia with severe features. Evaluating MAP at these time points may be useful for identifying women at higher risk for postpartum readmission. These women may otherwise be missed based on standard clinical approaches and may benefit from heightened surveillance. KEY POINTS/CONCLUSIONS:· Existing literature focuses on management of antenatal hypertensive disorders of pregnancy.. · Elevated peripartum MAP is associated with increased odds of readmission for preeclampsia.. · Peripartum MAP may predict readmission risk for de novo postpartum preeclampsia..
PMID: 37385293
ISSN: 1098-8785
CID: 5540492

Apples, oranges, and ectopic pregnancies [Editorial]

Meyer, Jessica A; Quinn, Gwendolyn P; Penfield, Christina A
PMID: 36858166
ISSN: 1556-5653
CID: 5462312

Reproductive Health in Congenital Heart Disease: Preconception, Pregnancy, and Postpartum

Halpern, Dan G; Penfield, Christina A; Feinberg, Jodi L; Small, Adam J
The prevalence of congenital heart disease (CHD) in pregnancy is rising due to the improved survival of patients with CHD into childbearing age. The profound physiological changes that occur during pregnancy may worsen or unmask CHD, affecting both mother and fetus. Successful management of CHD during pregnancy requires knowledge of both the physiological changes of pregnancy and the potential complications of congenital heart lesions. Care of the CHD patient should be based on a multidisciplinary team approach beginning with preconception counseling and continuing into conception, pregnancy, and postpartum periods. This review summarizes the published data, available guidelines and recommendations for the care of CHD during pregnancy.
PMID: 37233153
ISSN: 2308-3425
CID: 5543922

Comparison of pregnancy latency in preterm preeclampsia with oral labetalol versus extended-release nifedipine [Meeting Abstract]

Torres, A M; Meyer, J A; Lantigua-Martinez, M V; Friedman, S; Hade, E M; Roman, A S; Penfield, C A
Objective: To compare pregnancy latency achieved with oral labetalol versus extended-release nifedipine during expectant management of preterm preeclampsia with severe features (PEC-SF).
Study Design: This is a retrospective cohort study of patients initiated on antihypertensive therapy with oral labetalol or extended-release nifedipine during admission for expectant management of PEC-SF < 34 weeks between 1/2013 and 4/2022. Those on antihypertensive therapy prior to admission or with another indication for delivery < 34 weeks were excluded (monochorionic-monoamniotic twins, higher order multiples, absent or reversed umbilical artery Dopplers). Pregnancy latency (from oral agent initiation to delivery decision) was compared between groups. Secondary outcomes included need for initial agent dose uptitration, addition of second oral agent, acute antihypertensive therapy, and delivery for refractory hypertension. Linear and modified Poisson regression models were used to estimate adjusted mean differences (AMD) with 95% confidence intervals.
Result(s): The cohort included 78 patients (Table 1). Comparing those initiated on labetalol versus extended-release nifedipine (Table 2), there was no difference in latency (6.2 (7.5) vs 5.4 (7.4) days, AMD 1.1 days, 95% CI [-2.1, 4.4]), nor in the proportion of patients achieving 1 week latency (25.0% vs 23.8%, respectively, AMD 2.9%, 95% CI [-16.5, 22.3]). Those initiated on labetalol were less likely to require a second agent (16.7% vs 38.1% for nifedipine, AMD -18.4, 95% CI [-37.3, 0.5]). There were no differences in need for initial agent uptitration, acute antihypertensive therapy, or delivery for refractory hypertension.
Conclusion(s): There was no difference in pregnancy latency among patients with PEC-SF initiated on oral labetalol versus extended-release nifedipine. Patients on labetalol may be less likely to require a second antihypertensive agent, but comparative outcome estimates may be limited by small cohort size. Further investigations with a larger cohort should be performed to evaluate for any relative advantages of the two oral agents. [Formula presented] [Formula presented]
ISSN: 1097-6868
CID: 5512872

A randomized trial of the impact of postpartum ibuprofen on severe hypertensive disorders of pregnancy [Meeting Abstract]

Penfield, C A; Nageotte, M P; Oakes, M C; Marty, L; Caballero, D; Berger, D S; McNulty, J
Objective: To evaluate the impact of ibuprofen on postpartum (PP) blood pressure (BP) outcomes in pregnant patients with a new diagnosis of hypertensive disorders of pregnancy (HDP) and antenatal severe hypertension.
Study Design: In this double-blind randomized controlled trial, participants with HDP with antenatal severe hypertension (systolic BP >= 160 or diastolic >= 105mmHg) were assigned to receive a PP scheduled analgesic regimen with either ibuprofen or acetaminophen (control). Scheduled antihypertensive medications were started PP only as needed to maintain BP < 150/100. The primary outcome was prevalence of severe hypertension during PP stay. Prespecified secondary outcomes included need for PP anithypertensive medication, escalation of scheduled antihypertensive regimen, average PP mean arterial pressure (MAP), patient satisfaction, breakthrough pain medication, PP length of stay (LOS), and diuresis (urine output >= 200 ml/hour for 4 hours).
Result(s): From January 2017 to October 2019, 140 participants were randomized. Baseline characteristics were similar (Table 1). Prevalence of PP severe hypertension did not differ between groups (39.1% for those receiving ibuprofen vs 41.4% for controls, p=0.78, Table 2). There was no difference in PP antihypertensive medication use (35.7% in the ibuprofen group vs 40.0% for controls, p=0.60), nor escalation of scheduled antihypertensive regimen (15.7% in both groups, p=1.0). Mean MAP was similar between ibuprofen and control groups (95.7+/-8.2 vs 95.9+/-9.5, respectively, p=0.91). Diuresis occurred in 64.7% of the ibuprofen group vs 65.7% in controls (p=0.90). Patient satisfaction, breakthrough pain medication, and LOS were similar.
Conclusion(s): In patients with antenatal HDP and severe hypertension, PP ibuprofen use did not increase the prevalence of severe hypertension compared to those not receiving nonsteroidal antiinflammatory drugs (NSAIDs). Ibuprofen use did not impact other BP outcomes, pain control, or patient satisfaction. These findings from the largest trial to date support ACOG's recommendation that NSAIDs should be used preferentially over opioid analgesics. [Formula presented] [Formula presented]
ISSN: 1097-6868
CID: 5512892

COVID-19 transmissibility during labor and vaginal delivery [Letter]

Hawks, Rebecca J Mahn; Ades, Veronica; Roman, Ashley S; Penfield, Christina A; Goddard, Brian
PMID: 36240987
ISSN: 2589-9333
CID: 5361262

Postpartum Readmissions for Hypertensive Disorders in Pregnancy During the COVID-19 Pandemic

Griffin, Myah M; Black, Mara; Deeb, Jessica; Penfield, Christina A; Hoskins, Iffath A
Background/UNASSIGNED:Hypertensive disorders in pregnancy are one of the most common causes of readmission postpartum. Due to the COVID-19 pandemic, early hospital discharge was encouraged for patients who were medically stable as hospitalization rates among COVID-infected patients steadily increased in 2020. The impact of an early discharge policy on postpartum readmission rates among patients with hypertensive disorders in pregnancy is unknown. Objective/UNASSIGNED:To compare the postpartum readmission rates of patients with hypertensive disorders in pregnancy before and after implementation of an early discharge policy due to the COVID-19 pandemic. Study Design/UNASSIGNED:This is a quality improvement, retrospective cohort study of postpartum patients with antenatal hypertensive disorders in pregnancy who delivered and were readmitted due to hypertensive disorders in pregnancy at NYU Langone Health on 3/1/2019-2/29/2020 (control cohort) to 4/1/2020-3/31/2021 (COVID cohort). During the pandemic, our institution introduced an early discharge policy for all postpartum patients to be discharged no later than 2 days postpartum during the delivery admission if deemed medically appropriate. The reduction of postpartum length of stay was accompanied by the continuation of patient education, home blood pressure monitoring, and outpatient follow-up. The primary outcome was the comparison of the postpartum hypertensive disorders in pregnancy readmission rates. Data were analyzed using Fisher's Exact test, chi-square test, and Wilcoxon rank-sum test with significance defined as p<0.05. Results/UNASSIGNED:There was no statistical difference in readmission rates for postpartum hypertensive disorders in pregnancy before versus after implementation of an early discharge policy (1.08% for control cohort vs 0.59% for COVID cohort). Demographics in each group were similar, as were median times to readmission (5.0 days, IQR 4.0-6.0 days vs 6.0 days, IQR 5.0-6.0 days, p=0.13) and median readmission lengths of stay (3.0 days, IQR 2.0-4.0 days vs 3.0 days, IQR 2.0-4.0 days, p=0.45). There was one ICU readmission in the COVID cohort and none in the control cohort (p=0.35). There were no severe maternal morbidities or maternal deaths. Conclusion/UNASSIGNED:These findings suggest policies reducing postpartum length of stay, which includes patients with hypertensive disorders in pregnancy, can be implemented without impacting the hospital readmission rate for patients with hypertensive disorders in pregnancy. Continuation of patient education and outpatient surveillance during the pandemic was instrumental in the outpatient postpartum management of the study cohort. Further investigation into best practices to support early discharges is warranted.
PMID: 36164558
ISSN: 2666-5778
CID: 5334132

The association of inflammatory markers in pregnant women with COVID-19 disease severity [Meeting Abstract]

Wei, Lili S.; Trostle, Megan E.; Limaye, Meghana A.; Friedman, Steven; Penfield, Christina A.; Roman, Ashley S.
ISSN: 0002-9378
CID: 5242512


Buyon, J; Deonaraine, K; Carlucci, P; Masson, M; Fraser, N; Phoon, C; Roman, A; Izmirly, P; Saxena, A; Belmont, M; Penfield, C; Mi, Lee Y; Nusbaum, J; Solitar, B; Malik, F; Rackoff, P; Haberman, R; Acherman, R; Sinkovskaya, E; Albuhamad, A; Makhoul, M; Satou, G; Pinto, N; Moon-Grady, A; Howley, L; Levasseur, S; Matta, J; Lindblade, C; Rubenstein, A; Haxel, C; Kohari, K; Copel, J; Strainic, J; Doan, T; Bermudez-Wagner, K; Sheth, S S; Killen, S; Tacy, T; Kaplinski, M; Drewes, B; Clancy, R; Cuneo, B
Introduction Fetal cardiac disease is strongly associated with maternal anti-SSA/Ro antibodies, but gaps in our knowledge include the influence of antibody specificity and titer, maternal diagnosis, overall non-cardiac adverse pregnancy outcomes (APOs), optimal surveillance protocols, and efficacy of rapid treatment. Methods The multi-center Surveillance and Treatment To Prevent Fetal AV Block Likely to Occur Quickly (STOP BLOQ) study recruited pregnant women with commercially positive anti-Ro antibodies and stratified them into high and low titers of anti-Ro60 and Ro52 based on a research ELISA, using a cutoff defined by that obtained for 50 mothers with previous AVB offspring. Mothers with anti-Ro60 and/or 52 antibodies at or above 1,000 I.U. were trained to perform FHRM. From 17-25 weeks of gestation, FHRM was completed 3x/day in addition to weekly or biweekly fetal echocardiograms (echo). Mothers texted all audio sounds to the coordinating center. Texts deemed abnormal by mothers were immediately sent to an on call pediatric cardiologist who either reassured if FHRM was normal or referred for emergency fetal echo in < 6 hours if abnormal. Results 250 anti-Ro pregnant women (22% Hispanic, 50% white, 12% Black, 12% Asian, 4% other) have been consented, including 28 whose previous child had AVB. Of mothers tested to date, 153 were provided home monitors given high titer anti-Ro60 and/or 52 antibodies (26 high titer anti-Ro60 alone, 21 high titer anti-Ro52 alone,105 high titer antibodies to both antigens). The 83 patients with low titers were surveilled with echos per local standard of care. Regarding maternal diagnosis, of 161 assessed to date, 39% were asym/UAS, 11% RA, 31% SS, 19% SLE. Antibody titers did not significantly differ by ethnicity, race or diagnosis (table 1). Non-AVB APOs occurred in 18% and were not predicted by Ro60 or 52 titers but rather SLE diagnosis (table 2). In total, 24,759 FHRM audiotexts were received from 131 patients (90 of whom have delivered) during the monitoring period. Of these, 22 were evaluated by the on-call pediatric cardiologist, who prompted an emergency echo (all completed in < 6 hrs). In 11 cases, the emergency echo was normal. In 9, there were premature atrial contractions, confirming the mother's perception. In 2 with 2degree block on urgent echo (both treated per protocol with IVIG and dexamethasone), 1 reverted to normal sinus rhythm and the other progressed to 3degree block. In 2 others, the mother did not perceive abnormal FHRM for > 24 hrs, echo identified 3degree block, and retrospective cardiology review of FHRM audio captures identified an abnormality prior to obtaining the echo. All 4 AVB developed in fetuses of mothers with high titer antibodies to both Ro60 and 52 (mean 32,451 and 34,991 respectively). Of the 18 mothers with a previous AVB child who followed the 400mg hydroxychloroquine PATCH protocol, 1 developed AVB in accord with the results of Step 1 in that study. Conclusion These data support that APOs in this clinically diverse group of mothers are not influenced by anti-Ro titer or specificity, but rather SLE diagnosis. All conduction defects were initially identified by FHRM and in mothers with high titer anti-Ro60 and 52. Hydroxychloroquine continues to show efficacy in reducing the AVB recurrence rate with rapid intervention of emergent block being promising
ISSN: 2053-8790
CID: 5513372